NASDAQ:PRTK

Paratek Pharmaceuticals Stock Forecast, Price & News

$8.26

+0.04 (+0.49 %)

(As of 04/13/2021 03:44 PM ET)

Add

Compare

Today's Range

$7.98

Now: $8.26▼

$8.44

50-Day Range

$6.84

MA: $7.43▼

$8.16

52-Week Range

$3.81

Now: $8.26▼

$8.75

Volume15,778 shs

Average Volume475,671 shs

Market Capitalization$387.34 million

P/E RatioN/A

Dividend YieldN/A

Beta1.62

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNASDAQ:PRTK

Previous SymbolNASDAQ:TSPT

CUSIP89354M10

CIK1178711

Webwww.paratekpharma.com

Phone617-807-6600

Employees101

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio8.52

Quick Ratio7.67

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$16.54 million

Price / Sales23.42

Cash FlowN/A

Price / Cash FlowN/A

Book Value($1.19) per share

Price / Book-6.94

Profitability

EPS (Most Recent Fiscal Year)($3.93)

Net Income$-128,790,000.00

Net Margins-248.03%

Return on EquityN/A

Return on Assets-43.44%

Miscellaneous

Outstanding Shares46,893,000

Market Cap$387.34 million

Next Earnings Date5/10/2021 (Estimated)

OptionableOptionable

Headlines

Paratek (PRTK) Moves 14.5% Higher: Will This Strength Last?
April 12, 2021 | finance.yahoo.com

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK): Is Breakeven Near?
April 12, 2021 | finance.yahoo.com

Stock Traders Buy Large Volume of Call Options on Paratek Pharmaceuticals (NASDAQ:PRTK)
April 9, 2021 | americanbankingnews.com

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Expected to Announce Quarterly Sales of $32.83 Million
March 30, 2021 | americanbankingnews.com

Paratek Pharmaceuticals (PRTK) Q4 2020 Earnings Call Transcript
February 25, 2021 | finance.yahoo.com

Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Misses Revenue Estimates
February 24, 2021 | nasdaq.com

Paratek Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
February 24, 2021 | seekingalpha.com

Paratek Pharmaceuticals Announces Full Year 2020 Total Revenue of $46.9 Million including NUZYRA® (omadacycline) Net U.S. Sales of $38.8 Million
February 24, 2021 | finance.yahoo.com

Paratek Pharmaceuticals to Present at the 10th Annual SVB Leerink Global Healthcare Conference
February 18, 2021 | finance.yahoo.com

Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021
February 17, 2021 | finance.yahoo.com

Some Analysts Just Cut Their Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) Estimates
February 10, 2021 | finance.yahoo.com

Paratek Announces Expansion of NUZYRA(R) Launch into the Community Setting
February 8, 2021 | marketwatch.com

Paratek Announces Expansion of NUZYRA® Launch into the Community Setting
February 8, 2021 | finance.yahoo.com

Paratek Pharmaceuticals to Present at the 2021 H.C. Wainwright BIOCONNECT Virtual Conference
January 6, 2021 | finance.yahoo.com

Paratek Pharma Secures $60M Loan To Repay Hercules Capital
January 5, 2021 | nasdaq.com

Paratek Pharmaceuticals Receives $60 Million Non-Recourse Loan from R-Bridge Healthcare Investment Advisory, Ltd., an affiliate of CBC Group
January 4, 2021 | finance.yahoo.com

How Much Did Paratek Pharmaceuticals'(NASDAQ:PRTK) Shareholders Earn From Share Price Movements Over The Last Five Years?
December 25, 2020 | finance.yahoo.com

Notable Monday Option Activity: PRTK, WBA, CTAS
December 21, 2020 | nasdaq.com

Is PRTK A Good Stock To Buy Now?
December 11, 2020 | finance.yahoo.com

Paratek Pharmaceuticals: 100%+ Upside As Nuzyra Sales Scale
December 1, 2020 | seekingalpha.com

See More Headlines

MarketRank^™

Overall MarketRank^™

1.51 out of 5 stars

Medical Sector

503rd out of 2,016 stocks

Pharmaceutical Preparations Industry

245th out of 771 stocks

3.5 Analyst's Opinion

Consensus Rating
Paratek Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $17.00, Paratek Pharmaceuticals has a forecasted upside of 107.3% from its current price of $8.20.
Amount of Analyst Coverage
Paratek Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Paratek Pharmaceuticals has received 427 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Paratek Pharmaceuticals has received 384 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Paratek Pharmaceuticals has received 52.65% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Paratek Pharmaceuticals and other stocks. Vote “Outperform” if you believe PRTK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PRTK will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Paratek Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Paratek Pharmaceuticals does not have a long track record of dividend growth.

0.8 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Paratek Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.70% of the stock of Paratek Pharmaceuticals is held by insiders.
Percentage Held by Institutions
49.03% of the stock of Paratek Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Paratek Pharmaceuticals are expected to grow in the coming year, from ($1.68) to ($0.42) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Paratek Pharmaceuticals is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Paratek Pharmaceuticals is -3.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

$8.26

+0.04 (+0.49 %)

(As of 04/13/2021 03:44 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive PRTK News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTK and its competitors with MarketBeat's FREE daily newsletter.

Paratek Pharmaceuticals (NASDAQ:PRTK) Frequently Asked Questions

Is Paratek Pharmaceuticals a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Paratek Pharmaceuticals stock.
View analyst ratings for Paratek Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Paratek Pharmaceuticals?

Wall Street analysts have given Paratek Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Paratek Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Paratek Pharmaceuticals' next earnings date?

Paratek Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Paratek Pharmaceuticals.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its earnings results on Wednesday, February, 24th. The specialty pharmaceutical company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by $0.57. The specialty pharmaceutical company had revenue of $16.02 million for the quarter, compared to analyst estimates of $39.58 million.
View Paratek Pharmaceuticals' earnings history.

How has Paratek Pharmaceuticals' stock been impacted by Coronavirus?

Paratek Pharmaceuticals' stock was trading at $3.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, PRTK stock has increased by 111.8% and is now trading at $8.24.
View which stocks have been most impacted by COVID-19.

What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?

Paratek Pharmaceuticals issued an update on its FY 2021 After-Hours earnings guidance on Wednesday, February, 24th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $166-177 million, compared to the consensus revenue estimate of $182.84 million.

What price target have analysts set for PRTK?

3 Wall Street analysts have issued 12-month price objectives for Paratek Pharmaceuticals' stock. Their forecasts range from $14.00 to $22.00. On average, they expect Paratek Pharmaceuticals' share price to reach $17.00 in the next year. This suggests a possible upside of 106.3% from the stock's current price.
View analysts' price targets for Paratek Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Paratek Pharmaceuticals' key executives?

Paratek Pharmaceuticals' management team includes the following people:

Mr. Michael F. Bigham CPA, M.B.A., CPA, MBA, Exec. Chairman (Age 63, Pay $881.68k)
Dr. Evan Loh, CEO & Director (Age 62, Pay $906.9k)
Mr. Adam Woodrow, Pres & Chief Commercial Officer (Age 54, Pay $672.21k)
Mr. William M. Haskel, Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer (Age 59, Pay $586k)
Ms. Sarah Higgins, VP, Controller and Interim Principal Financial & Accounting Officer (Age 46)
Mr. Jason Burdette, Sr. VP of Technical Operations
Mr. Ben Strain, VP of Investor Relations & Corp. Communications and Chief of Staff to the CEO
Ms. Christine R. Coyne M.B.A., VP of Marketing
Ms. Karen McGrath, Sr. VP of HR
Mr. Randall B. Brenner, Chief Devel. & Regulatory Officer (Age 48)

Who are some of Paratek Pharmaceuticals' key competitors?

Some companies that are related to Paratek Pharmaceuticals include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly and (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics Public (HZNP), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Nektar Therapeutics (NKTR), Pacira BioSciences (PCRX), Corcept Therapeutics (CORT) and Supernus Pharmaceuticals (SUPN).
View all of PRTK's competitors.

What other stocks do shareholders of Paratek Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL).

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $8.24.

How much money does Paratek Pharmaceuticals make?

Paratek Pharmaceuticals has a market capitalization of $386.40 million and generates $16.54 million in revenue each year. The specialty pharmaceutical company earns $-128,790,000.00 in net income (profit) each year or ($3.93) on an earnings per share basis.

How many employees does Paratek Pharmaceuticals have?

Paratek Pharmaceuticals employs 101 workers across the globe.

What is Paratek Pharmaceuticals' official website?

The official website for Paratek Pharmaceuticals is www.paratekpharma.com.

Where are Paratek Pharmaceuticals' headquarters?

Paratek Pharmaceuticals is headquartered at 75 PARK PLAZA, BOSTON MA, 02116.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The specialty pharmaceutical company can be reached via phone at 617-807-6600 or via email at [email protected]

This page was last updated on 4/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here